U.O. Oncologia 2 Universitaria A.O.U. Pisana
Welcome,         Profile    Billing    Logout  
 4 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pedersini, Rebecca RP
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
BDMO, NCT06367491: National Database of Bone Metastases

Recruiting
N/A
800
Europe
Registration in a database
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Bone Metastases
01/30
01/30
HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Recruiting
N/A
150
Europe
University of Milano Bicocca
Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
01/24
01/24
PALMARES-2, NCT06805812: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian Study

Recruiting
N/A
3500
Europe
Palbociclib, Ribociclib, Abemaciclib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, European Institute of Oncology, Italy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, OSPEDALE ASST CREMONA, IOV Oncologico Veneto Padova, ASST Fatebenefratelli Sacco, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, A.O.U. Federico II, Napoli, San Raffaele University Hospital, Italy, Centro di Riferimento Oncologico - Aviano, Azienda Socio-Sanitaria Territoriale Lariana, Azienda ULSS 3 Serenissima, Ospedale di Mirano, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliero-Universitaria Careggi, Humanitas, Istituto Clinico Catanese, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Fondazione Policlinico Universitario Campus Bio-Medico, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors
12/30
12/40
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
GIM29-GIMOMIC, NCT06871501: "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Not yet recruiting
N/A
1000
Europe
Consorzio Oncotech
Breast Cancer
05/25
11/26
Fontana, Andrea
FOENIX-MBC2 TAS-120-201, NCT04024436 / 2019-001164-30: A Study of TAS-120 in Patients With Metastatic Breast Cancer

Completed
2
168
Europe, Canada, US
Futibatinib, TAS-120, Futibatinib plus Fulvestrant
Taiho Oncology, Inc., Taiho Pharma Europe Limited, TAIHO ONCOLOGY INC.
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
05/23
10/24
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting
N/A
10000
Europe
Consorzio Oncotech
Metastatic Breast Cancer
06/23
12/25
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pedersini, Rebecca RP
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
BDMO, NCT06367491: National Database of Bone Metastases

Recruiting
N/A
800
Europe
Registration in a database
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Bone Metastases
01/30
01/30
HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Recruiting
N/A
150
Europe
University of Milano Bicocca
Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
01/24
01/24
PALMARES-2, NCT06805812: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian Study

Recruiting
N/A
3500
Europe
Palbociclib, Ribociclib, Abemaciclib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, European Institute of Oncology, Italy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, OSPEDALE ASST CREMONA, IOV Oncologico Veneto Padova, ASST Fatebenefratelli Sacco, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, A.O.U. Federico II, Napoli, San Raffaele University Hospital, Italy, Centro di Riferimento Oncologico - Aviano, Azienda Socio-Sanitaria Territoriale Lariana, Azienda ULSS 3 Serenissima, Ospedale di Mirano, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliero-Universitaria Careggi, Humanitas, Istituto Clinico Catanese, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Fondazione Policlinico Universitario Campus Bio-Medico, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors
12/30
12/40
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
GIM29-GIMOMIC, NCT06871501: "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Not yet recruiting
N/A
1000
Europe
Consorzio Oncotech
Breast Cancer
05/25
11/26
Fontana, Andrea
FOENIX-MBC2 TAS-120-201, NCT04024436 / 2019-001164-30: A Study of TAS-120 in Patients With Metastatic Breast Cancer

Completed
2
168
Europe, Canada, US
Futibatinib, TAS-120, Futibatinib plus Fulvestrant
Taiho Oncology, Inc., Taiho Pharma Europe Limited, TAIHO ONCOLOGY INC.
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
05/23
10/24
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting
N/A
10000
Europe
Consorzio Oncotech
Metastatic Breast Cancer
06/23
12/25
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25

Download Options